Therefore, the majority of clinical trials of novel agents in combination with R-CHOP as front-line treatment of DLBCL that are currently underway are specifically targeting the ABC subtype of DLBCL. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.